Affiliation(s):
Department of Laboratory Medicine, Wujin Hospital Affiliated with Jiangsu University, Jiangsu University, 213017 Changzhou, Jiangsu Province, China;;
moreAffiliation(s): Department of Laboratory Medicine, Wujin Hospital Affiliated with Jiangsu University, Jiangsu University, 213017 Changzhou, Jiangsu Province, China;; Department of Laboratory Medicine, School of Medicine, Jiangsu University, 212013 Zhenjiang, Jiangsu Province, China;; Changzhou Key Laboratory of Molecular Diagnostics and Precision Cancer Medicine (Wujin Clinical College of Xuzhou Medical University), 213017 Changzhou, Jiangsu Province, China;
less
Yanjin WANG, Yifei CHEN, Fuji YANG, Xiaolong YU, Ying CHU, Jing ZHOU, Yongmin YAN, Jianbo XI. MiR4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2300305
@article{title="MiR4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression", author="Yanjin WANG, Yifei CHEN, Fuji YANG, Xiaolong YU, Ying CHU, Jing ZHOU, Yongmin YAN, Jianbo XI", journal="Journal of Zhejiang University Science B", year="in press", publisher="Zhejiang University Press & Springer", doi="https://doi.org/10.1631/jzus.B2300305" }
%0 Journal Article %T MiR4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression %A Yanjin WANG %A Yifei CHEN %A Fuji YANG %A Xiaolong YU %A Ying CHU %A Jing ZHOU %A Yongmin YAN %A Jianbo XI %J Journal of Zhejiang University SCIENCE B %P %@ 1673-1581 %D in press %I Zhejiang University Press & Springer doi="https://doi.org/10.1631/jzus.B2300305"
TY - JOUR T1 - MiR4465-modified mesenchymal stem cell-derived small extracellular vesicles inhibit liver fibrosis development via targeting LOXL2 expression A1 - Yanjin WANG A1 - Yifei CHEN A1 - Fuji YANG A1 - Xiaolong YU A1 - Ying CHU A1 - Jing ZHOU A1 - Yongmin YAN A1 - Jianbo XI J0 - Journal of Zhejiang University Science B SP - EP - %@ 1673-1581 Y1 - in press PB - Zhejiang University Press & Springer ER - doi="https://doi.org/10.1631/jzus.B2300305"
Abstract: liver fibrosis is a significant health burden, marked by the consistent deposition of collagen. Unfortunately, the currently available treatment approaches for this condition are far from optimal. Lysyl oxidase-like protein 2 (LOXL2) secreted by hepatic stellate cells (HSC) is a crucial player in the cross-linking of matrix collagen and is a significant target for treating liver fibrosis. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEV) have been proposed as a potential treatment option for chronic liver disorders. Previous studies have found that MSC-sEV can be used for miRNA delivery into target cells or tissues. It is currently unclear whether miR4465 can target LOXL2 and inhibit HSC activation. Additionally, it is uncertain whether MSC-sEV can be utilized as a gene therapy vector to carry miR4465 and effectively inhibit the progression of liver fibrosis. This study explored the effect of miR4465-modified MSC-sEV (MSC-sEVmiR4465) on LOXL2 expression and liver fibrosis development. The results showed that miR4465 can bind specifically to the promoter of the LOXL2 gene in HSC. Moreover, MSC-sEVmiR4465 inhibited HSC activation and collagen expression by downregulating LOXL2 expression in vitro. MSC-sEVmiR4465 injection could reduce HSC activation and collagen deposition in the CCl4-induced mouse model. MSC-sEVmiR4465 mediating via LOXL2 also hindered the migration and invasion of HepG2 cells. In conclusion, we found that MSC-sEV can deliver miR4465 into HSC to alleviate liver fibrosis via altering LOXL2, which might provide a promising therapeutic strategy for liver diseases.
Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference
Open peer comments: Debate/Discuss/Question/Opinion
Open peer comments: Debate/Discuss/Question/Opinion
<1>